This is the authors' abstract. We don't add key points for this paper.
A scalable route to 1-(5-(4-(3-hydroxy-3-methylbutyl)-1 H -1,2,3-triazol-1-yl)-4-(isopropylamino)pyridin-2-yl)-1 H -pyrazolo[3,4- b ]pyridine-5-carbonitrile ( 1, BMS-986236 ) was developed by incorporating an alternate azide intermediate following safety-driven processes. The newly developed process involved mitigating safety hazards and eliminating the column chromatography purification. The issue of trace metal contamination in the final API observed in the first-generation synthesis has been overcome.
No takes yet. Share an insight, caveat, or question.
Arunachalam et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: